Header Logo

Connection

JASVINDER SINGH to Treatment Outcome

Back to Details
This is a "connection" page, showing publications JASVINDER SINGH has written about Treatment Outcome.
JASVINDER SINGH
Connection Strength
2.215
Treatment Outcome
  1. Development of classification and response criteria for rheumatic diseases. Arthritis Rheum. 2006 Jun 15; 55(3):348-52.
    View in: PubMed
    Score: 0.061
  2. Re: Roxana Ramos, Ethan Ferguson, Mahmoud Abou Zeinab, et al. Single-port Transvesical Robot-assisted Simple Prostatectomy: Surgical Technique and Clinical Outcomes. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.11.012. Eur Urol. 2024 Sep; 86(3):e73.
    View in: PubMed
    Score: 0.053
  3. Making the current non-surgical treatments for knee osteoarthritis more effective: Solutions from a diverse patient group. Joint Bone Spine. 2023 05; 90(3):105535.
    View in: PubMed
    Score: 0.048
  4. Treatment Guidelines in Rheumatoid Arthritis. Rheum Dis Clin North Am. 2022 08; 48(3):679-689.
    View in: PubMed
    Score: 0.046
  5. Belimumab for systemic lupus erythematosus. Cochrane Database Syst Rev. 2021 02 25; 2:CD010668.
    View in: PubMed
    Score: 0.042
  6. A Randomized Internet-Based Pilot Feasibility and Planning Study of Cherry Extract and Diet Modification in Gout. J Clin Rheumatol. 2020 Jun; 26(4):147-156.
    View in: PubMed
    Score: 0.040
  7. Spondyloarthritis is associated with higher healthcare utilization and complication rates after primary total knee or total hip arthroplasty. Clin Rheumatol. 2020 Aug; 39(8):2345-2353.
    View in: PubMed
    Score: 0.040
  8. Validation of the Hip Disability and Osteoarthritis Outcome Score and Knee Injury and Osteoarthritis Outcome Score Pain and Function Subscales for Use in Total Hip Replacement and Total Knee Replacement Clinical Trials. J Arthroplasty. 2020 05; 35(5):1200-1207.e4.
    View in: PubMed
    Score: 0.039
  9. Age, race, comorbidity, and insurance payer type are associated with outcomes after total ankle arthroplasty. Clin Rheumatol. 2020 Mar; 39(3):881-890.
    View in: PubMed
    Score: 0.039
  10. Factors Influencing the Effectiveness of Allopurinol in Achieving and Sustaining Target Serum Urate in a US Veterans Affairs Gout Cohort. J Rheumatol. 2020 03; 47(3):449-460.
    View in: PubMed
    Score: 0.038
  11. Individualized decision aid for diverse women with lupus nephritis (IDEA-WON): A randomized controlled trial. PLoS Med. 2019 05; 16(5):e1002800.
    View in: PubMed
    Score: 0.037
  12. Gout and healthcare utilization and complications after hip arthroplasty: a cohort study using the US National Inpatient Sample (NIS). Clin Rheumatol. 2019 Apr; 38(4):1213-1216.
    View in: PubMed
    Score: 0.037
  13. Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. Arthritis Care Res (Hoboken). 2019 01; 71(1):2-29.
    View in: PubMed
    Score: 0.036
  14. Medicaid or Medicare insurance payer status and household income are associated with outcomes after primary total hip arthroplasty. Clin Rheumatol. 2018 Sep; 37(9):2489-2496.
    View in: PubMed
    Score: 0.035
  15. Developing a core outcome domain set to assessing effectiveness of interdisciplinary multimodal pain therapy: the VAPAIN consensus statement on core outcome domains. Pain. 2018 04; 159(4):673-683.
    View in: PubMed
    Score: 0.035
  16. Consensus on draft OMERACT core domains for clinical trials of Total Joint Replacement outcome by orthopaedic surgeons: a report from the International consensus on outcome measures in TJR trials (I-COMiTT) group. BMC Musculoskelet Disord. 2017 01 26; 18(1):45.
    View in: PubMed
    Score: 0.032
  17. Achieving Consensus on Total Joint Replacement Trial Outcome Reporting Using the OMERACT Filter: Endorsement of the Final Core Domain Set for Total Hip and Total Knee Replacement Trials for Endstage Arthritis. J Rheumatol. 2017 Nov; 44(11):1723-1726.
    View in: PubMed
    Score: 0.032
  18. An underlying diagnosis of osteonecrosis of bone is associated with worse outcomes than osteoarthritis after total hip arthroplasty. BMC Musculoskelet Disord. 2017 01 09; 18(1):8.
    View in: PubMed
    Score: 0.032
  19. Increasing comorbidity is associated with worsening physical function and pain after primary total knee arthroplasty. BMC Musculoskelet Disord. 2016 10 07; 17(1):421.
    View in: PubMed
    Score: 0.031
  20. Comparative effectiveness of immunosuppressive drugs and corticosteroids for lupus nephritis: a systematic review and network meta-analysis. Syst Rev. 2016 09 13; 5(1):155.
    View in: PubMed
    Score: 0.031
  21. Risk of serious infections with immunosuppressive drugs and glucocorticoids for lupus nephritis: a systematic review and network meta-analysis. BMC Med. 2016 Sep 13; 14(1):137.
    View in: PubMed
    Score: 0.031
  22. Assessment of physical function and participation in chronic pain clinical trials: IMMPACT/OMERACT recommendations. Pain. 2016 Sep; 157(9):1836-1850.
    View in: PubMed
    Score: 0.031
  23. Treatments for Lupus Nephritis: A Systematic Review and Network Metaanalysis. J Rheumatol. 2016 10; 43(10):1801-1815.
    View in: PubMed
    Score: 0.031
  24. Clinically important improvement thresholds for Harris Hip Score and its ability to predict revision risk after primary total hip arthroplasty. BMC Musculoskelet Disord. 2016 06 10; 17:256.
    View in: PubMed
    Score: 0.030
  25. A Real-World Study of Switching From Allopurinol to Febuxostat in a Health Plan Database. J Clin Rheumatol. 2015 Dec; 21(8):411-8.
    View in: PubMed
    Score: 0.029
  26. Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort. Arthritis Res Ther. 2015 May 12; 17:120.
    View in: PubMed
    Score: 0.028
  27. Rheumatoid arthritis is associated with higher ninety-day hospital readmission rates compared to osteoarthritis after hip or knee arthroplasty: a cohort study. Arthritis Care Res (Hoboken). 2015 May; 67(5):718-24.
    View in: PubMed
    Score: 0.028
  28. Does hospital volume predict outcomes and complications after total shoulder arthroplasty in the US? Arthritis Care Res (Hoboken). 2015 May; 67(6):885-90.
    View in: PubMed
    Score: 0.028
  29. Are there racial disparities in utilization and outcomes after total elbow arthroplasty? Rheumatol Int. 2015 Sep; 35(9):1479-87.
    View in: PubMed
    Score: 0.028
  30. Racial disparities in total ankle arthroplasty utilization and outcomes. Arthritis Res Ther. 2015 Mar 21; 17:70.
    View in: PubMed
    Score: 0.028
  31. Increasing obesity and comorbidity in patients undergoing primary total hip arthroplasty in the U.S.: a 13-year study of time trends. BMC Musculoskelet Disord. 2014 Dec 17; 15:441.
    View in: PubMed
    Score: 0.027
  32. Sex differences in characteristics, utilization, and outcomes of patient undergoing total elbow arthroplasty: a study of the US nationwide inpatient sample. Clin Rheumatol. 2016 Mar; 35(3):723-31.
    View in: PubMed
    Score: 0.027
  33. Time trends in the characteristics of patients undergoing primary total knee arthroplasty. Arthritis Care Res (Hoboken). 2014 Jun; 66(6):897-906.
    View in: PubMed
    Score: 0.026
  34. Depression in primary TKA and higher medical comorbidities in revision TKA are associated with suboptimal subjective improvement in knee function. BMC Musculoskelet Disord. 2014 Apr 11; 15:127.
    View in: PubMed
    Score: 0.026
  35. Challenges faced by patients in gout treatment: a qualitative study. J Clin Rheumatol. 2014 Apr; 20(3):172-4.
    View in: PubMed
    Score: 0.026
  36. Predictors of pain medication use for arthroplasty pain after revision total knee arthroplasty. Rheumatology (Oxford). 2014 Oct; 53(10):1752-8.
    View in: PubMed
    Score: 0.026
  37. Application of the OMERACT filter to measures of core outcome domains in recent clinical studies of acute gout. J Rheumatol. 2014 Mar; 41(3):574-80.
    View in: PubMed
    Score: 0.026
  38. OMERACT endorsement of measures of outcome for studies of acute gout. J Rheumatol. 2014 Mar; 41(3):569-73.
    View in: PubMed
    Score: 0.026
  39. Better functional and similar pain outcomes in osteoarthritis compared to rheumatoid arthritis after primary total knee arthroplasty: a cohort study. Arthritis Care Res (Hoboken). 2013 Dec; 65(12):1936-41.
    View in: PubMed
    Score: 0.026
  40. Diabetes: a risk factor for poor functional outcome after total knee arthroplasty. PLoS One. 2013; 8(11):e78991.
    View in: PubMed
    Score: 0.025
  41. Patients with osteoarthritis and avascular necrosis have better functional outcomes and those with avascular necrosis worse pain outcomes compared to rheumatoid arthritis after primary hip arthroplasty: a cohort study. BMC Med. 2013 Sep 24; 11:210.
    View in: PubMed
    Score: 0.025
  42. Operative diagnosis for revision total hip arthroplasty is associated with patient-reported outcomes (PROs). BMC Musculoskelet Disord. 2013 Jul 17; 14:210.
    View in: PubMed
    Score: 0.025
  43. Medical comorbidity is associated with persistent index hip pain after total hip arthroplasty. Pain Med. 2013 Aug; 14(8):1222-9.
    View in: PubMed
    Score: 0.025
  44. Ipsilateral lower extremity joint involvement increases the risk of poor pain and function outcomes after hip or knee arthroplasty. BMC Med. 2013 Jun 05; 11:144.
    View in: PubMed
    Score: 0.025
  45. Cerebrovascular disease is associated with outcomes after total knee arthroplasty: a US total joint registry study. J Arthroplasty. 2014 Jan; 29(1):40-3.
    View in: PubMed
    Score: 0.025
  46. Income and patient-reported outcomes (PROs) after primary total knee arthroplasty. BMC Med. 2013 Mar 06; 11:62.
    View in: PubMed
    Score: 0.024
  47. Crystal arthritis: Is HLAB genotyping the future of gout pharmacogenomics? Nat Rev Rheumatol. 2013 Apr; 9(4):200-2.
    View in: PubMed
    Score: 0.024
  48. Patient-level clinically meaningful improvements in activities of daily living and pain after total hip arthroplasty: data from a large US institutional registry. Rheumatology (Oxford). 2013 Jun; 52(6):1109-18.
    View in: PubMed
    Score: 0.024
  49. Medical and psychological comorbidity predicts poor pain outcomes after total knee arthroplasty. Rheumatology (Oxford). 2013 May; 52(5):916-23.
    View in: PubMed
    Score: 0.024
  50. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012 May; 64(5):625-39.
    View in: PubMed
    Score: 0.023
  51. Risk factors for revision surgery after humeral head replacement: 1,431 shoulders over 3 decades. J Shoulder Elbow Surg. 2012 Aug; 21(8):1039-44.
    View in: PubMed
    Score: 0.022
  52. Association of peptic ulcer disease and pulmonary disease with risk of periprosthetic fracture after primary total knee arthroplasty. Arthritis Care Res (Hoboken). 2011 Oct; 63(10):1471-6.
    View in: PubMed
    Score: 0.022
  53. Smoking as a risk factor for short-term outcomes following primary total hip and total knee replacement in veterans. Arthritis Care Res (Hoboken). 2011 Oct; 63(10):1365-74.
    View in: PubMed
    Score: 0.022
  54. Hospital volume and surgical outcomes after elective hip/knee arthroplasty: a risk-adjusted analysis of a large regional database. Arthritis Rheum. 2011 Aug; 63(8):2531-9.
    View in: PubMed
    Score: 0.022
  55. OMERACT 10 Patient Perspective Virtual Campus: valuing health; measuring outcomes in rheumatoid arthritis fatigue, RA sleep, arthroplasty, and systemic sclerosis; and clinical significance of changes in health. J Rheumatol. 2011 Aug; 38(8):1728-34.
    View in: PubMed
    Score: 0.022
  56. Validation of pain and patient global scales in chronic gout: data from two randomised controlled trials. Ann Rheum Dis. 2011 Jul; 70(7):1277-81.
    View in: PubMed
    Score: 0.022
  57. Patient-reported outcomes in chronic gout: a report from OMERACT 10. J Rheumatol. 2011 Jul; 38(7):1452-7.
    View in: PubMed
    Score: 0.022
  58. Smoking and outcomes after knee and hip arthroplasty: a systematic review. J Rheumatol. 2011 Sep; 38(9):1824-34.
    View in: PubMed
    Score: 0.022
  59. Responsiveness differences in outcome instruments after revision hip arthroplasty: what are the implications? BMC Musculoskelet Disord. 2011 May 23; 12:107.
    View in: PubMed
    Score: 0.021
  60. Botulinum toxin for shoulder pain: a cochrane systematic review. J Rheumatol. 2011 Mar; 38(3):409-18.
    View in: PubMed
    Score: 0.021
  61. Surgery for shoulder osteoarthritis: a Cochrane systematic review. J Rheumatol. 2011 Apr; 38(4):598-605.
    View in: PubMed
    Score: 0.021
  62. Tocilizumab for rheumatoid arthritis: a Cochrane systematic review. J Rheumatol. 2011 Jan; 38(1):10-20.
    View in: PubMed
    Score: 0.021
  63. Intraarticular botulinum toxin A for refractory painful total knee arthroplasty: a randomized controlled trial. J Rheumatol. 2010 Nov; 37(11):2377-86.
    View in: PubMed
    Score: 0.020
  64. Golimumab for rheumatoid arthritis: a systematic review. J Rheumatol. 2010 Jun; 37(6):1096-104.
    View in: PubMed
    Score: 0.020
  65. Newer biological agents in rheumatoid arthritis: impact on health-related quality of life and productivity. Drugs. 2010; 70(2):121-45.
    View in: PubMed
    Score: 0.019
  66. A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview. CMAJ. 2009 Nov 24; 181(11):787-96.
    View in: PubMed
    Score: 0.019
  67. Trial sample size, but not trial quality, is associated with positive study outcome. J Clin Epidemiol. 2010 Feb; 63(2):154-62.
    View in: PubMed
    Score: 0.019
  68. Anakinra for rheumatoid arthritis: a systematic review. J Rheumatol. 2009 Jun; 36(6):1118-25.
    View in: PubMed
    Score: 0.019
  69. Quality of life and quality of care for patients with gout. Curr Rheumatol Rep. 2009 Apr; 11(2):154-60.
    View in: PubMed
    Score: 0.019
  70. Intra-articular botulinum toxin A for refractory shoulder pain: a randomized, double-blinded, placebo-controlled trial. Transl Res. 2009 May; 153(5):205-16.
    View in: PubMed
    Score: 0.018
  71. Improved health-related quality of life with effective disease-modifying antirheumatic drugs: evidence from randomized controlled trials. Am J Manag Care. 2008 Apr; 14(4):234-54.
    View in: PubMed
    Score: 0.017
  72. Improved health-related quality of life with effective disease-modifying antirheumatic drugs: evidence from randomized controlled trials. Am J Manag Care. 2007 Dec; 13 Suppl 9:S237-51.
    View in: PubMed
    Score: 0.017
  73. Contributions of OMERACT to rheumatic disease research. Arthritis Rheum. 2007 Feb 15; 57(1):186.
    View in: PubMed
    Score: 0.016
  74. Systemic treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials. J Allergy Clin Immunol. 2023 12; 152(6):1470-1492.
    View in: PubMed
    Score: 0.013
  75. Serum urate as a proposed surrogate outcome measure in gout trials: From the OMERACT working group. Semin Arthritis Rheum. 2021 12; 51(6):1378-1385.
    View in: PubMed
    Score: 0.011
  76. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2021 07; 73(7):924-939.
    View in: PubMed
    Score: 0.011
  77. Improving Benefit-harm Assessment of Therapies from the Patient Perspective: OMERACT Premeeting Toward Consensus on Core Sets for Randomized Controlled Trials. J Rheumatol. 2019 08; 46(8):1053-1058.
    View in: PubMed
    Score: 0.009
  78. Outcome Measures in Rheumatology - Interventions for medication Adherence (OMERACT-Adherence) Core Domain Set for Trials of Interventions for Medication Adherence in Rheumatology: 5 Phase Study Protocol. Trials. 2018 Mar 27; 19(1):204.
    View in: PubMed
    Score: 0.009
  79. Serum urate as surrogate endpoint for flares in people with gout: A systematic review and meta-regression analysis. Semin Arthritis Rheum. 2018 10; 48(2):293-301.
    View in: PubMed
    Score: 0.009
  80. Weight loss for overweight and obese individuals with gout: a systematic review of longitudinal studies. Ann Rheum Dis. 2017 Nov; 76(11):1870-1882.
    View in: PubMed
    Score: 0.008
  81. Outcome Measures Used in Arthroplasty Trials: Systematic Review of the 2008 and 2013 Literature. J Rheumatol. 2017 08; 44(8):1277-1287.
    View in: PubMed
    Score: 0.008
  82. Defining the optimal biological monotherapy in rheumatoid arthritis: A systematic review and meta-analysis of randomised trials. Semin Arthritis Rheum. 2017 06; 46(6):699-708.
    View in: PubMed
    Score: 0.008
  83. Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis. Ann Rheum Dis. 2016 Oct; 75(10):1813-8.
    View in: PubMed
    Score: 0.007
  84. Developing core outcome measurement sets for clinical trials: OMERACT filter 2.0. J Clin Epidemiol. 2014 Jul; 67(7):745-53.
    View in: PubMed
    Score: 0.007
  85. Outcome measures in acute gout: a systematic literature review. J Rheumatol. 2014 Mar; 41(3):558-68.
    View in: PubMed
    Score: 0.006
  86. Does clinically important change in function after knee replacement guarantee good absolute function? The multicenter osteoarthritis study. J Rheumatol. 2014 Jan; 41(1):60-4.
    View in: PubMed
    Score: 0.006
  87. Including health equity considerations in development of instruments for rheumatology research: an introduction to a novel OMERACT paradigm. J Rheumatol. 2014 Jan; 41(1):150-2.
    View in: PubMed
    Score: 0.006
  88. The influence of the contralateral knee prior to knee arthroplasty on post-arthroplasty function: the multicenter osteoarthritis study. J Bone Joint Surg Am. 2013 Jun 05; 95(11):989-93.
    View in: PubMed
    Score: 0.006
  89. Total knee arthroplasty volume, utilization, and outcomes among Medicare beneficiaries, 1991-2010. JAMA. 2012 Sep 26; 308(12):1227-36.
    View in: PubMed
    Score: 0.006
  90. Improved health-related quality of life and physical function in patients with refractory chronic gout following treatment with pegloticase: evidence from phase III randomized controlled trials. J Rheumatol. 2012 Jul; 39(7):1450-7.
    View in: PubMed
    Score: 0.006
  91. OARSI/OMERACT initiative to define states of severity and indication for joint replacement in hip and knee osteoarthritis. An OMERACT 10 Special Interest Group. J Rheumatol. 2011 Aug; 38(8):1765-9.
    View in: PubMed
    Score: 0.005
  92. Tophus measurement as an outcome measure for clinical trials of chronic gout: progress and research priorities. J Rheumatol. 2011 Jul; 38(7):1458-61.
    View in: PubMed
    Score: 0.005
  93. Bringing it all together: a novel approach to the development of response criteria for chronic gout clinical trials. J Rheumatol. 2011 Jul; 38(7):1467-70.
    View in: PubMed
    Score: 0.005
  94. Minimally important differences of the gout impact scale in a randomized controlled trial. Rheumatology (Oxford). 2011 Jul; 50(7):1331-6.
    View in: PubMed
    Score: 0.005
  95. Variation in outcome measures in hip and knee arthroplasty clinical trials: a proposed approach to achieving consensus. J Rheumatol. 2009 Sep; 36(9):2050-6.
    View in: PubMed
    Score: 0.005
  96. Intra-articular Botulinum Toxin Type A: a new approach to treat arthritis joint pain. Toxicon. 2009 Oct; 54(5):658-67.
    View in: PubMed
    Score: 0.005
  97. A modified Delphi exercise to determine the extent of consensus with OMERACT outcome domains for studies of acute and chronic gout. Ann Rheum Dis. 2008 Jun; 67(6):888-91.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.